REVIEW ARTICLE Hypertension in the meta bolic syndrome
dysfunction, early carotid atherosclerosis, impaired aortic distensibility, hypertensive retinopathy and microalbuminuria in hypertensive patients with MS have been described when compared to those without it. 21 The importance of MS diagnosis and of its individual components in the prognostic value of hypertensives has been analyzed in a limited number of studies, supporting the added risk of the metabolic components beyond the high BP values. The Copenhagen Male Study 22 with 2,906 participants demonstrated that men with high BP and dyslipidemia had higher risk as compared to those high BP without dyslipidemia. In the 1,742 hypertensives of the Progetto Ipertensione Umbria Monitoraggi (PIUMA) cohort, those with MS had an almost doubled cardiovascular event rate compared to those without risk. 23 Likewise, among 2,225 men and women followed up for a mean of 4.1 years, subjects defined as dyslipemic hypertensives had a higher cardiovascular risk compared to hypertensives in the absence of dyslipidemia. 24 In the Hoorn study 25 , 615 men and 749 women, aged 50 to 75, followed up to 10 years and without diabetes or a history of cardiovascular disease at baseline MS were associated with a higher cardiovascular disease risk.
The Pressioni Arteriose Monitorate E Loro Associazioni (PAMELA) study has recently provided further data on the association of MS with cardiovascular risk. 26 Over 148 months of follow-up, the risk of cardiovascular and all-cause death was significantly higher in MS individuals, the difference vs. those without this condition remaining significant (about 70% and 40%, respectively) after adjustment for differences in age, gender, and other cardiovascular risk factors.
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Treatment of hypertension in the meta bolic syndrome
The objective of MS treatment is both to reduce high cardiovascular and renal risk associated with individual components of the MS and to reduce the risk of developing type-2 diabetes. Specific pharmaco logical agents which inter fere at the core of the MS are not yet available. Partial approaches have been developed and insulin-sensitizing drugs and endocannabinoid receptor C1 blockers exert a beneficial effect on the main components of the syndrome but their overall effect of the MS in uncontrolled hypertensives as compared to subjects with BP under control has also been described. 9 It may reflect the more difficult BP control in subjects with a cluster of cardiovascular risk factors and/or higher degrees of end-organ damage.
Links between hypertension in the meta bolic syndrome Despite close association between the MS components and high BP, the understanding of individual contribution of some of the MS components to the increment in BP levels is complex, since each of them inter acts with other MS components and with mechanisms inducing hypertension. The central role of obesity and IR in the rise of BP values has been recognized for many years. These abnormalities lead to overactivity of the sympathetic 15, 16 and renin-angiotensin systems 15 , abnormal renal sodium handling 17 , and endothelial dysfunction (FIGuRE) [18] [19] [20] . Beside the contribution to the BP rise, cross-sectional and follow-up studies have demonstrated that MS increases the risk for hypertension-induced kidney disease. Increased prevalence of left ventricular hypertrophy, diastolic 29 The shift in fat storage, moving from visceral to subcutaneous fat and increasing weight, and fluid retention are the main side effects of the drugs, which limit their use. Even more important is the potential increment of cardiovascular risk in subjects treated with rosiglitazone that seems to be absent when pioglitazone is used. Whichever the case, there has been no approval for the MS so far.
Targeting elevated blood pressure/hypertension
The threshold for inter vention in BP values is based on the recognition that underlying risk factors raise BP to ranges that increase the risk of cardiovascular disease. Furthermore, subjects with the MS seem to be at risk of developing hypertension. Consequently, 130/85 mmHg should be the threshold for inter vention in the absence of diabetes, although when BP is <140/90 mmHg and no organ damage is present, non-pharmacological treatment needs to be introduced first.
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Hypertension should be managed according to the individual risk assessment of the European Society of Hypertension (ESH)/European Society of Cardiology guidelines.
30 If diabetes is present, antihypertensive drugs should be introduced at even lower levels, 130/80 mmHg. 32 The goal is to maintain BP <130/80 mmHg.
Treatment of high BP in the MS should be based on lifestyle changes, diet and physical exercise, which reduce weight and improve muscular blood flow. As far as antihypertensive drugs are concerned, whether or not a particular antihypertensive agent is superior to others, they have not been tested in trials including subjects specifically with the MS. However, a large body of information is available from both long-term on cardiovascular risk, quality of life and mood has raised concerns about their use. Consequently, it is currently necessary to treat individual components of the syndrome in order to reduce risk level associated with each component, thereby reducing their overall effect on cardiovascular, renal, and diabetes risks (TABLE 2).
Targeting meta bolic syndrome mechanisms All current guidelines on the management of individual components of the MS emphasize that a change in lifestyle, particularly weight loss and physical activity, is first-line therapy. Extreme diets are seldom effective in inducing long-term weight reduction. A modest calorie reduction (500-1000 cal/day) is usually more effective and beneficial for long-term weight loss. A realistic goal is to reduce body weight by 7-10% over a period of 6-12 months. Long-term maintenance of weight loss is then best achieved when regular exercise is part of weight reduction management.
27 Current guidelines recommend a daily minimum of 30 minutes of moderate-intensity physical activity.
28 Smoking cessation is mandatory. Lifestyle inter vention is unfortunately often neglected in routine practice despite its potential to reduce the severity of all meta bolic risk factors and to slow their progress.
Beside the positive effect of physical exercise and weight loss on the mechanisms leading to the MS, there has been, to date, one type of drugs inter fering with one of the key MS mechanisms -the insulin-sensitizers. They increase peripheral glucose uptake by acting through the peroxisome proliferator-activated receptor-γ (PPARγ). The effect of this drug class on BP values is not well established yet, although some evidence points to a beneficial effect in terms of BP reduction, at least in type-2 diabetes individuals and those with refractory hypertension. However, improve glucose disposal. Another putative mechanism by which the inhibition of the renin-angiotensin system may improve insulin sensitivity is through effects on PPARγ, which is inhibited by angiotensin II.
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The impact of other antihypertensive drug classes demonstrated the neutral meta bolic effect of both long-acting CCBs, as well as other sympaticolytic drugs with central action such as reserpine, α-methyl-dopa or moxonidine. The pure peripheral α-blocker, doxasozin, improves lipid profile reducing IR and consequently increasing high -density lipoprotein cholesterol and reducing triglycerides. 33 A trend to reduce total cholesterol has also been described. The main mechanism implicated in the positive changes of α-blockers seems to be mediated by increasing microcirculation flow. Additional effects of α-blockade on the activity of the key lipid meta bolism enzymes are less known.
A final question is the net effect of the interaction when 2 different kinds of drugs with opposite effects are combined. This is the case of combination treatments with diuretics. Simultaneous administration of thiazide diuretic with ACEI or ARBs reduces the hypokaliemia and does not significantly modify lipid and glucose profiles. Whether or not this combination substantially reduces the beneficial effects in cardiovascular risk needs to be assessed. A recent publication points out that valsartan alone reduced the levels of high sensitivity C-reactive protein (hsCRP). 42 In contrast, a combination of valsartan plus hydrochlorotiazide, despite a significantly larger BP reduction, was unable to reduce the level of hsCRP. No inter action with statins was demonstrated.
ConCLusIons Recently the ESH acknowledges the clinical relevance of the MS in hypertension. 21 The MS is a frequent clinical condition among hypertensive subjects and its prevalence has been on the increase driven by the obesity epidemic. It increases the cardiovascular and renal risk associated with hypertension. Consequently, the thresholds to initiate antihypertensive treatment and the goals to be achieved need to be redefined. Drugs which potentially lead to worsened meta bolic profile should be avoided unless compelling indications exist. antihypertensive trials with major outcomes and a myriad of shorter studies.
After changes to lifestyle have been introduced, the drugs to be used should be the ones which may induce reduction of IR and subsequent changes in lipid profile and glucose levels. Therefore, angiotensin-converting enzyme inhibitors (ACEI), angiotensin II receptor blockers (ARB) or even calcium channel blockers are preferable over diuretics and β-blockers in monotherapy, if no compelling indications are present for its use. If a combination of drugs is required, low-range doses of diuretics can be used.
The effect of particular antihypertensive drugs on other components of the MS is an important clinical issue with consequences for the success of the treatment. Changes in lipid profile and IR during antihypertensive treatment with diuretics and β-blockers have been reported to be responsible for lower reductions in coronary heart disease morbidity and mortality than expected. 33 On the contrary, the reduction in new-onset diabetes rate has been observed during treatment with ACEI, ARB or even calcium channel blockers (CCB) as compared to diuretics and β-blockers.
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The most recognized meta bolic change associated with antihypertensive drug classes is IR. It is induced by a combination of different mechanisms including reduction of the microcirculatory flow in the muscles and impaired in intracellular glucose disposal rate. The former is a consequence of the use of β-blockers, since β-blockade activity goes unopposed by the α-receptors. The latter is not as well understood. β-blocker agents with additional properties can reduce the impact of the pure β-blockade and even exert a partially beneficial effect. The simultaneous α-blockade of carvedilol 37 or the increase in the nitric oxide bio availability of nebivolol 38 have shown a neutral effect on glucose meta bolism indexes and a trend towards a favorable lipid profile 39,40 .
The reduction of glucose disposal is worse when insulin secretion decreases. This can occur as a direct consequence of the β-blockade, reducing the response of the pancreatic β-cell, and by hypokaliemia induced by thiazide-like diuretics. Reductions in glucose disposal and in the compensatory insulin secretion lead to meta bolic abnormalities of the glucose homeostasis and dyslipidemia, as previously described.
Nevertheless, a beneficial effect on decreasing the risk for the development of diabetes with ACEI or ARB-based treatments has been described. Detailed systematic reviews of the potential beneficial effects have been published recently. In general, treatment with these drug classes reduces the rate of new-onset diabetes as compared with the use of diuretic and/or β-blockers.
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Inhibiting the renin-angiotensin system may improve blood flow to muscles, decrease the activity of the sympathetic nervous system, enhance insulin signaling, lower free fatty acids levels, increase plasma adiponectin levels, and
